Clinical trials
Completed Phase 2 Small Cell Lung Carcinoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
148 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 9 |
| 2001 | 2 |
| 2002 | 6 |
| 2003 | 6 |
| 2004 | 5 |
| 2005 | 6 |
| 2006 | 14 |
| 2007 | 7 |
| 2008 | 10 |
| 2009 | 12 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 5 |
| 2016 | 6 |
| 2017 | 6 |
| 2018 | 6 |
| 2019 | 3 |
| 2020 | 7 |
| 2021 | 8 |
| 2022 | 2 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 148 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 18 |
| SCRI Development Innovations, LLC | 5 |
| Alliance for Clinical Trials in Oncology | 3 |
| British Columbia Cancer Agency | 3 |
| Celgene | 3 |
| Eli Lilly and Company | 3 |
| GlaxoSmithKline | 3 |
| National Cancer Center, Korea | 3 |
| Novartis Pharmaceuticals | 3 |
| University of Colorado, Denver | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Small Cell Lung Carcinoma | 148 |
| Lung Neoplasms | 51 |
| Carcinoma, Non-Small-Cell Lung | 31 |
| Breast Neoplasms | 8 |
| Head and Neck Neoplasms | 8 |
| Neoplasms | 6 |
| Pancreatic Neoplasms | 6 |
| Melanoma | 5 |
| Ovarian Neoplasms | 5 |
| Squamous Cell Carcinoma of Head and Neck | 5 |
Trials
Showing 1 to 25 of 148. Each trial links to its page on Pharma Observatory.
48 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.